Navigation Links
Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
Date:12/18/2007

RICHMOND, Va., Dec. 18 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for IPLEX(TM) for the treatment of Myotonic Muscular Dystrophy (MMD). Insmed is currently conducting a 24-week Phase III enabling trial for IPLEX(TM) in MMD, and recently was awarded a grant of approximately $2.1 million from the Muscular Dystrophy Association (MDA), which is expected to cover a substantial portion of the external costs associated with the trial.

"This Orphan Drug Designation is another milestone for Insmed in our development and commercialization plan for IPLEX(TM) in MMD," said Geoffrey Allan Ph.D., Insmed's President and Chief Executive Officer. "Orphan status, combined with the recent $2.1 million MDA grant, positions us well to continue advancing this important product candidate through clinical development, and maximize the market opportunities for MMD available to us."

Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 Americans annually. This orphan drug designation for IPLEX(TM), grants Insmed seven years of market exclusivity upon approval for the MMD indication. In addition, Insmed is eligible for tax credits relative to its development costs, as well as assistance from the FDA in advancing the drug candidate through the regulatory process.

MMD affects approximately 37,000 Americans, and nearly 60,000 people in the European Union. MMD is a genetic disease characterized by endurance loss, muscle wasting, weakness, pain, cognitive impairment and gastro-intestinal dysfunction. There is currently no cure for the disease, and no specific treatment has been developed to satisfactorily reverse or ameliorate the common symptoms associated with the disease.

About IPLEX(TM) <
'/>"/>

SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3New test for safer biomedical research results 53248 1New test for safer biomedical research results 53248 2Sun exposure may trigger certain autoimmune diseases in women 53245 1Sun exposure may trigger certain autoimmune diseases in women 53245 2Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2
...tion at 24 Months, SAN DIEGO, Dec. 12 Ceregene, ... a Phase 1 clinical trial of CERE-120 in 12,patien...s gene therapy to,deliver the neural growth factor...that occurs in the brains of Parkinson,s disease,p... 24 months post,treatment, suggest a sustained red...
... Inc., a,biotechnology company developing orally a...at the Company has initiated a multi-dose trial wi...ent for smallpox infection. This,trial will study ...the drug,given to healthy volunteers., "The high ...ase I trial,has validated the utility of the compa...
Other Medicine Technology:Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 2Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 3Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease 4Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection 2
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...vide Market-Leading Dental Tools and Services to ...NAPOLIS, April 29 WellPoint, Inc. (NYSE:,WLP), th...announced the,acquisition of DeCare Dental, one of...roup customers. The acquisition of,DeCare enhances...
...ril 29 Hundreds of,bicyclists are expected to par...e-day fundraising ride starting in Newton, Massach...is July 18-20. The event and its,participants rais...mmer, the Trek is distributing cowbells in the,com...
... LAUNCHES, FREDERICK, Md., April 29 BioElectroni...ew website, http://www.actipatch.it ,is now selli...SS Medical,(Tecnica Scientifica Service), designed...uartered in Torino, Italy. Over,10,000 ActiPatch u...
...pril 29 In conjunction,with DURECT Corporation,s ...lts press release, you are invited to listen to th... the Internet on Wednesday, May 7th, 2008,at 4:30 ... by accessing,DURECT,s homepage at http://www.dur...
...50 had agreement on standard outcomes, review find...- Few studies consider the appropriate measurement...hildren, say University of Liverpool researchers w...ldren in the process to select which measurements ...
...may now be predicted more realistically according ...rnal of Clinical Endocrinology & Metabolism (JCEM)...MH) levels are related to the onset of menopause a... small follicles present in a womans ovaries. This...
Other Medicine News:Health News:WellPoint Announces Acquisition of DeCare Dental 2Health News:WellPoint Announces Acquisition of DeCare Dental 3Health News:WellPoint Announces Acquisition of DeCare Dental 4Health News:WellPoint Announces Acquisition of DeCare Dental 5Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 2Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 3Health News:BioElectronics Corporation Announces New Website for Italian Market 2Health News:BioElectronics Corporation Announces New Website for Italian Market 3Health News:Measurements Poor for Assessing Clinical Trials With Children 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: